Amedeo Smart

Free Medical Literature Service


 

Amedeo

Diseases of the Thyroid

  Free Subscription

Articles published in
J Nucl Med
    March 2024
  1. GREENSPAN BS, Hofman MS, Buscombe J
    Commentary on "Radioactive Iodine: A Living History".
    J Nucl Med. 2024;65:495.
    >> Share

    December 2023
  2. VENTURA D, Dittmann M, Buther F, Schafers M, et al
    Diagnostic Performance of [(18)F]TFB PET/CT Compared with Therapeutic Activity [(131)I]Iodine SPECT/CT and [(18)F]FDG PET/CT in Recurrent Differentiated Thyroid Carcinoma.
    J Nucl Med. 2023 Dec 21:jnumed.123.266513. doi: 10.2967/jnumed.123.266513.
    >> Share

    November 2023
  3. GUNTHER T, Holzleitner N, Viering O, Beck R, et al
    Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [(68)Ga]Ga-DOTA-CCK-66 PET/CT in 2 Patients with Medullary Thyroid Cancer.
    J Nucl Med. 2023 Nov 9:jnumed.123.266537. doi: 10.2967/jnumed.123.266537.
    >> Share

  4. VIERING O, Gunther T, Holzleitner N, Dierks A, et al
    CCK(2) Receptor-Targeted PET/CT in Medullary Thyroid Cancer Using [(68)Ga]Ga-DOTA-CCK-66.
    J Nucl Med. 2023 Nov 2:jnumed.123.266380. doi: 10.2967/jnumed.123.266380.
    >> Share

    October 2023
  5. LASCHINSKY C, Theurer S, Herold T, Rawitzer J, et al
    Molecular Markers Are Associated with Onset of Radioiodine Refractoriness in Patients with Papillary Thyroid Carcinoma.
    J Nucl Med. 2023 Oct 26:jnumed.123.266044. doi: 10.2967/jnumed.123.266044.
    >> Share

    June 2023
  6. ENKE JS, Bundschuh RA, Wienand G, Reitsam NG, et al
    Somatostatin Receptor Antagonists as a Theranostic Option in Iodine-Refractory Thyroid Carcinoma.
    J Nucl Med. 2023 Jun 15:jnumed.123.265639. doi: 10.2967/jnumed.123.265639.
    >> Share

    April 2023
  7. TAPROGGE J, Abreu C, Yusuf S, Ainsworth G, et al
    The Role of Pretherapy Quantitative Imaging and Dosimetry in Radioiodine Therapy for Advanced Thyroid Cancer.
    J Nucl Med. 2023 Apr 28:jnumed.122.264913. doi: 10.2967/jnumed.122.264913.
    >> Share

    January 2023
  8. VON GUGGENBERG E, Uprimny C, Klingler M, Warwitz B, et al
    Preliminary clinical experience of cholecystokinin-2 receptor PET/CT imaging using the (68)Ga-labeled minigastrin analog DOTA-MGS5 in patients with medullary thyroid cancer.
    J Nucl Med. 2023 Jan 19:jnumed.122.264977. doi: 10.2967/jnumed.122.264977.
    >> Share

    December 2022
  9. HERRMANN K, Giovanella L, Santos A, Gear J, et al
    Joint EANM, SNMMI, and IAEA Enabling Guide: How to Set up a Theranostics Center.
    J Nucl Med. 2022;63:1836-1843.
    >> Share

    November 2022
  10. OEVERHAUS M, Koenen J, Bechrakis N, Stohr M, et al
    Radioiodine ablation of thyroid remnants in patients with Graves' orbitopathy.
    J Nucl Med. 2022 Nov 23:jnumed.122.264660. doi: 10.2967/jnumed.122.264660.
    >> Share

    June 2022
  11. AVRAM AM, Giovanella L, Greenspan B, Lawson SA, et al
    SNMMI Procedure Standard/EANM Practice Guideline for Nuclear Medicine Evaluation and Therapy of Differentiated Thyroid Cancer: Abbreviated Version.
    J Nucl Med. 2022;63:15N-35N.
    >> Share

    February 2022
  12. SIGNORE A, Campagna G, Marinaccio J, de Vitis M, et al
    Analysis of short term and stable DNA damage in patients with differentiated thyroid cancer treated with (131)I in hypothyroidism or with rhTSH for remnant ablation.
    J Nucl Med. 2022 Feb 3. pii: jnumed.121.263442. doi: 10.2967/jnumed.121.263442.
    >> Share

    August 2021
  13. AVRAM AM, Zukotynski K, Nadel HR, Giovanella LM, et al
    MANAGEMENT OF DIFFERENTIATED THYROID CANCER: THE STANDARD OF CARE.
    J Nucl Med. 2021 Aug 19. pii: jnumed.121.262402. doi: 10.2967/jnumed.121.262402.
    >> Share

    July 2021
  14. GIOVANELLA L, Avram A, Clerc J
    Molecular Imaging for Thyrotoxicosis and Thyroid Nodules.
    J Nucl Med. 2021;62.
    >> Share

  15. BERNET VJ, Chindris AM
    Update on the Evaluation of Thyroid Nodules.
    J Nucl Med. 2021;62.
    >> Share

    March 2021
  16. SEIFERT R, Schafers MA, Heitplatz B, Kerschke L, et al
    Minimal extrathyroid extension in papillary micro carcinoma of the thyroid is an independent risk factor for relapse through lymph node and distant metastases.
    J Nucl Med. 2021 Mar 26. pii: jnumed.121.261898. doi: 10.2967/jnumed.121.261898.
    >> Share

    February 2021
  17. MARIANI G, Tonaccehra M, Grosso M, Fiore E, et al
    The Role of Nuclear Medicine in the Clinical Management of Benign Thyroid Disorders. Part 2. Nodular Goiter, Hypothyroidism, and Subacute Thyroiditis.
    J Nucl Med. 2021 Feb 12. pii: jnumed.120.251504. doi: 10.2967/jnumed.120.251504.
    >> Share

  18. BODET-MILIN C, Faivre-Chauvet A, Carlier T, Ansquer C, et al
    Anti-CEA pretargeted Immuno-PET shows higher sensitivity than DOPA-PET/CT to detect relapsing metastatic medullary thyroid carcinoma: Post- hoc analysis of the iPET-MTC study.
    J Nucl Med. 2021 Feb 5. pii: jnumed.120.252791. doi: 10.2967/jnumed.120.252791.
    >> Share

    October 2020
  19. MARIANI G, Tonacchera M, Grosso M, Orsolini F, et al
    The role of nuclear medicine in the clinical management of benign thyroid disorders. Part 1. Hyperthyroidism.
    J Nucl Med. 2020 Oct 2. pii: jnumed.120.243170. doi: 10.2967/jnumed.120.243170.
    >> Share

    July 2020
  20. GRIMALDI S, Lagarde S, Harle JR, Boucraut J, et al
    Autoimmune encephalitis concomitant with SARS-CoV-2 infection: insight from (18)F-FDG PET imaging and neuronal autoantibodies.
    J Nucl Med. 2020 Jul 24. pii: jnumed.120.249292. doi: 10.2967/jnumed.120.249292.
    >> Share

    March 2020
  21. WU D, Gomes Lima CJ, Bloom G, Burman KD, et al
    Nationwide Survey on Implementation of 2011 Nuclear Regulatory Commission Policy on Release of Patients After (131)I Therapy for Thyroid Cancer.
    J Nucl Med. 2020;61:397-404.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016